



JAMMU AND KASHMIR MEDICAL SUPPLIES CORPORATION LTD.

(Public Sector Undertaking of Govt of Jammu & Kashmir)

Corporate Head Office: Plot No: 58, Friends Colony, Satyam Road, Trikuta Nagar Jammu

Corporate Office: Opp State Motor Garages Near Haj House, Bemina, Srinagar

Telephone: 0191-2580842, Fax: 0191-2581845 (Jammu); Telefax: 0194-2432008 (Srinagar)

Telefax: 0194-2432008 email: gmjjkmscl@gmail.com; website: www.jkmscl.nic.in

::NOTIFICATION::

E-Bid for the finalization of Rate Contract under Group **Allopathic Drugs/Medicines** was invited by the JKMSCL under **NIT No: JKMSCL/Drugs & Medicines/2023-2024/613 dated 05-02-2024**, wherein below item had been projected as Proprietary/Patented Product of Particular Manufacturer

S. No.	Name of Item	Bidder	Name of Manufacturer claiming Proprietary/ Patented	Rates offered by the bidder including taxes
1.	Inj. Nanosomal Paclitaxel 100mg Lyophilized	M/s Lupin Limited	Samyang biopharmaceuticals Corporation South Korea	11972.80

It is notified that in case any bidder / manufacturer/ importer have any objections / comments related to above mentioned item in terms of Proprietary / Patented Technology of the item mentioned above tendered under reference No: **JKMSCL/Drugs & Medicines/2023-2024/613 dated 05-02-2024**, as claimed by the Bidder please reply with proper justification/documents through e-mail on mdjkmscl2@gmail.com/ gmkjkmscl@gmail.com within 5 days from the date of issuance of this notification. Thereafter no objection shall be entertained. The details of propriety / patent certificates and tendered specifications are available on website of JKMSCL i.e. www.jkmsclbusiness.com

General Manager (K)
JKMSCL

No.: JKMSCL/613/2025/2795-90

Dated: 22-08-2025

Copy for information to the:-

- 1 Managing Director, JKMSCL
- 2 Financial Advisor /Chief Account Officer, JKMSCL.
- 3 General Manager (J) JKMSCL
- 4 I/c Website to upload the notification on the official website of JKMSCL.
- 5 Office Record.

•samyang•

Samyang Holdings Corporation

Plant address: 79, Sinildong-ro, Daedeok-gu, Daejeon, Republic of Korea

Office address: 295 Pangyo-ro, Bundang-gu, Seongnam-si, Gyeonggi-do, 13488, Korea

Tel: 82-2-2157-9861 Fax: 82-2-2157-9063

Dated: April 17, 2023

TO WHOMSOEVER IT MAY CONCERN

SAMYANG HOLDINGS CORPORATION, 295 Pangyo-ro, Bundang-gu, Seongnam-si, Gyeonggi-do, 13488, Korea hereby authorizes the following product is registered and marketed by **LUPIN LIMITED**, whose principal place of business is situated at Kalpataru Inspire Bldg., Opp Hotel Grand Hyatt, Santacruz-East. | Mumbai | 100055, who has the exclusive right to register and commercialize the following product on our behalf in the territory of India.

Samyang Holding is the innovator and the license holder of the unique formulation Genexol PM world over, Genexol PM: is marketed in India, Vietnam, Philippines, Thailand, Malaysia, Myanmar, Hungary, Georgia, Syria, and is under registration in Sri Lanka & has been used in more than 12,000 patients worldwide.

For India we have exclusively Licensed this formulation product to Lupin Limited and they are marketing this product for last 11 years.

Name of Product: Genexol-PM

(Paclitaxel injection containing 100mg paclitaxel in each vial)

Genexol-PM is water-soluble Polymeric Micelle formulation of paclitaxel. The Polymeric Micelle technology applied to the Genexol-Pm is an innovative nanotechnology platform enabling to make nano sized formulation of 20-50 nm in a biodegradable polymer without using the toxic solubilizing agents of injections such as Cremophor of conventional paclitaxel formulations.

This Power of Authorization will be valid from the valid date of agreement between Samyang Holdings Corporation and Lupin Limited and will be in force until its withdrawal.

•samyang•
Holdings

Authorized signed

Date: 17/April/2023

Lee Seon-mun, Sr. Manager



US011179466B2

(12) **United States Patent**
Kim et al.

(10) **Patent No.:** US 11,179,466 B2
(45) **Date of Patent:** Nov. 23, 2021

(54) **AMPHIPHILIC BLOCK COPOLYMER COMPOSITION HAVING ENHANCED MICELLE STABILITY, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME**

(71) Applicant: **SAMYANG HOLDINGS CORPORATION**, Seoul (KR)

(72) Inventors: **Bong Oh Kim**, Daejeon (KR); **Kyu Jin Kyung**, Yangju-si (KR); **Su Won Lee**, Seongnam-si (KR)

(73) Assignee: **SAMYANG HOLDINGS CORPORATION**, Seoul (KR)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

(21) Appl. No.: 16/469,392

(22) PCT Filed: Nov. 29, 2017

(86) PCT No.: PCT/KR2017/013863

§ 371 (c)(1),

(2) Date: Jun. 13, 2019

(87) PCT Pub. No.: WO2018/110870

PCT Pub. Date: Jun. 21, 2018

(65) **Prior Publication Data**

US 2019/0328880 A1 Oct. 31, 2019

(30) **Foreign Application Priority Data**

Dec. 14, 2016 (KR) 10-2016-0170266

(51) **Int. Cl.**

A61K 47/10

(2017.01)

A61K 9/107

(2006.01)

(Continued)

(52) **U.S. Cl.**

CPC A61K 47/10 (2013.01); A61K 9/1075 (2013.01); A61K 31/337 (2013.01); A61K 47/32 (2013.01);

(Continued)

(58) **Field of Classification Search**

CPC A61K 47/10
See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

2003/0143184 A1 7/2003 Seo et al.

2003/0180363 A1 9/2003 Seo et al.

(Continued)

FOREIGN PATENT DOCUMENTS

CN 106995528 A 8/2017

JP 2000-511161 A 8/2000

(Continued)

OTHER PUBLICATIONS

International Search Report issued in PCT/KR2017/013863 (PCT/ISA/210), dated Mar. 29, 2018.

(Continued)

Primary Examiner — Benjamin J Packard

(74) *Attorney, Agent, or Firm* — Birch, Stewart, Kolasch & Birch, LLP

(57) **ABSTRACT**

The present invention relates to an amphiphilic block copolymer composition which provides enhanced stability to a micelle formed by an amphiphilic block copolymer in an aqueous phase.

9 Claims, 2 Drawing Sheets

